Journal of Liver: Disease & TransplantationISSN: 2325-9612

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Editorial, J Liver Dis Transplant Vol: 3 Issue: 2

Hepatitis C: Success, but at a High Cost of Cure

Maxwell M Chait*
Assistant Professor of Medicine, College of Physicians and Surgeons of Columbia University, Columbia Doctors Medical Group, 180 East Hartsdale Avenue, Hartsdale, New York, USA
Corresponding author : Maxwell M. Chait MD FACP FACG AGAF FASGE
Assistant Professor of Medicine, College of Physicians and Surgeons of Columbia University, Columbia Doctors Medical Group, 180 East Hartsdale Avenue, Hartsdale, New York 10530, USA
E-mail: [email protected]
Received: October 14, 2014 Accepted: October 18, 2014 Published: October 24, 2014
Citation: Maxwell M Chait, et al (2014) Hepatitis C: Success, but at a High Cost of Cure J Liver:: Dis Transplant 3:2. doi:10.4172/2325-9612.1000e106

Abstract

Hepatitis C: Success, but at a High Cost of Cure

Hepatitis C is a chronic infection that afflicts approximately 170 million people worldwide with annual mortality of 350,000. There are approximately 15,000 deaths annually in the US. The US Food and Drug Administration (FDA) has recently approved the combination medication Ledipasvir/Sofosbuvir under the trade name of Harvoni with dramatically higher cure rates with fewer side effects than the interferon and ribavirin based regimens. The breakthrough treatment comes at a price that may place it out of reach for all but the wealthiest or best-insured patients.

Keywords:

Track Your Manuscript

Share This Page